Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Stock Has Consensus Price Target of $13.08 According to Brokerages

Shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) have been assigned a consensus rating of “Moderate Buy” from the nine analysts that are currently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and six have given a buy recommendation to the company. The average 12 month target price among analysts that have covered the stock in the last year is $13.08.

A number of equities analysts have recently weighed in on VNDA shares. HC Wainwright reaffirmed a “buy” rating and set a $20.00 target price on shares of Vanda Pharmaceuticals in a research report on Monday. B. Riley Financial restated a “buy” rating and set a $12.00 price target (down from $17.00) on shares of Vanda Pharmaceuticals in a research note on Monday, August 10th. Oppenheimer began coverage on shares of Vanda Pharmaceuticals in a report on Wednesday, September 23rd. They set an “outperform” rating and a $10.00 price objective on the stock. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Vanda Pharmaceuticals in a research note on Friday, July 17th.

Hedge Funds Weigh In On Vanda Pharmaceuticals

A number of hedge funds have recently added to or reduced their stakes in VNDA. Quantbot Technologies LP bought a new position in shares of Vanda Pharmaceuticals in the second quarter valued at approximately $29,000. Legal & General Group Plc bought a new position in shares of Vanda Pharmaceuticals during the 2nd quarter worth approximately $34,000. Allworth Financial LP purchased a new position in Vanda Pharmaceuticals in the second quarter worth $43,000. Caitong International Asset Management Co. Ltd boosted its position in Vanda Pharmaceuticals by 3,010.5% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 10,389 shares of the biopharmaceutical company’s stock worth $92,000 after purchasing an additional 10,055 shares during the last quarter. Finally, Walleye Capital LLC bought a new position in Vanda Pharmaceuticals in the 2nd quarter valued at $76,000. Institutional investors and hedge funds own 88.14% of the company’s stock.

Vanda Pharmaceuticals Stock Performance

Shares of Vanda Pharmaceuticals stock opened at $4.52 on Friday. Vanda Pharmaceuticals has a one year low of $4.27 and a one year high of $9.94. The firm has a market capitalization of $273.29 million, a price-to-earnings ratio of -0.98 and a beta of 0.69. The business has a 50-day simple moving average of $5.16 and a 200 day simple moving average of $5.97. The company has a debt-to-equity ratio of 0.01, a current ratio of 1.61 and a quick ratio of 1.60.

Vanda Pharmaceuticals (NASDAQ:VNDA) last posted its quarterly earnings results on Wednesday, August 5th. The biopharmaceutical company reported ($1.04) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.58) by ($0.46). Vanda Pharmaceuticals had a negative return on equity of 49.81% and a negative net margin of 127.41%.The firm had revenue of $50.53 million for the quarter, compared to analyst estimates of $61.92 million. On average, research analysts anticipate that Vanda Pharmaceuticals will post -3.02 earnings per share for the current fiscal year.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc is a biopharmaceutical company focused on developing and commercializing therapies for disorders of the central nervous system. The company was founded in 2003 and is headquartered in Washington, DC Its work centers on conditions involving sleep, circadian rhythms, and psychiatric health.

Vanda’s commercial products include Hetlioz (tasimelteon), a melatonin receptor agonist approved in the United States for Non-24-Hour Sleep-Wake Disorder and Smith-Magenis Syndrome, and Fanapt (iloperidone), an atypical antipsychotic used to treat schizophrenia in adults.